Estrella Immunopharma, Inc. develops clinical-stage ARTEMIS T-cell therapies for cancer and autoimmune diseases. Company updates center on its CD19-targeted lead candidate EB103, the CD19/CD22-targeted EB104 program, and STARLIGHT-1 clinical disclosures in B-cell non-Hodgkin lymphoma and other B-cell malignancy settings.
Recurring news also covers conference presentations, clinical data releases, financing transactions, analyst coverage, Nasdaq listing matters, and governance developments. Estrella's public securities include Nasdaq-listed common stock under ESLA and warrants under ESLAW.
Estrella Immunopharma (NASDAQ: ESLA) appointed Cynthia Pussinen Chief Executive Officer and Board Chairperson, effective October 25, 2026. She succeeds Cheng Liu as CEO. Liu becomes Chief Scientific Officer and remains President and a director. Pussinen brings more than 30 years of biotechnology and pharmaceutical leadership experience.
Estrella is advancing EB103 in STARLIGHT-1, a Phase I/II trial in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Early findings included durable complete responses in evaluable patients and no treatment-related serious adverse events in the initial dose-escalation population, supporting advancement into dose expansion. Pussinen will lead corporate and clinical development strategy, including advancing EB103, strengthening strategic and financial partnerships and expanding potential applications of the ARTEMIS T-cell therapy platform.
Estrella Immunopharma (ESLA) treated the first patient with two EB103 infusions in the dose-expansion phase of its STARLIGHT-1 trial. Each infusion delivered 5 × 10⁶ T cells/kg, three weeks apart, at the recommended Phase II dose. No treatment-related serious adverse events were reported through the first month of follow-up.
The Phase I/II trial evaluates investigational EB103 in relapsed or refractory B-cell non-Hodgkin's lymphoma. Earlier dose-escalation results showed a 100% complete response rate at Month 1 among evaluable high-dose patients, with no treatment-related serious adverse events among nine treated patients. All evaluable Phase I patients without central nervous system involvement who achieved a complete response remained in complete response at nine months. Estrella expects expansion-cohort data to inform its pivotal trial strategy; the latest safety finding covers only one patient.
Estrella Immunopharma (ESLA) activated its fifth clinical site for the STARLIGHT-1 Phase I/II trial evaluating EB103 in B-cell non-Hodgkin’s lymphoma.
The new site, Intermountain Health LDS Hospital in Salt Lake City, Utah, is expected to begin screening and enrolling patients after site initiation activities are completed. EB103 is an investigational CD19-targeted T-cell therapy being studied in patients whose lymphoma has returned or has not responded to treatment.
The ongoing dose-expansion phase is a multi-center, open-label study, meaning treatment assignments are known. It evaluates safety and efficacy at the recommended Phase II dose in adults aged 18 years or older. Estrella expects expansion-cohort data to inform its pivotal trial strategy for EB103. Other active sites are UC Davis, Baylor Scott & White, Oregon Health & Science University, and University Hospitals Cleveland Medical Center.
Estrella Immunopharma (NASDAQ: ESLA) has activated University Hospitals Cleveland Medical Center as the fourth clinical site for its ongoing Phase I/II STARLIGHT-1 trial of EB103, a CD19-redirected ARTEMIS T-cell therapy for adults with relapsed or refractory B-cell non-Hodgkin’s lymphoma.
The UH Cleveland Medical Center site, affiliated with Case Western Reserve University School of Medicine, is expected to begin screening and enrolling patients after completing site initiation activities. The expansion phase is a multi-center, open-label study evaluating the safety and efficacy of EB103 at the recommended Phase II dose and is expected to inform Estrella’s pivotal trial strategy. Active sites now include UC Davis Comprehensive Cancer Center, Baylor Scott & White Research Institute, Oregon Health & Science University, and UH Cleveland Medical Center. Trial details are listed under NCT06343311 on ClinicalTrials.gov.
Estrella Immunopharma (NASDAQ: ESLA) has activated Oregon Health & Science University in Portland as the third clinical site for its ongoing STARLIGHT-1 Phase I/II trial of EB103, a CD19-redirected ARTEMIS T-cell therapy for relapsed or refractory B-cell non-Hodgkin’s lymphoma.
The new site has begun screening and enrolling adult patients (≥18 years). The expansion phase is a multi-center, open-label study assessing the safety and efficacy of EB103 at the recommended Phase II dose. According to Estrella Immunopharma, data from this expansion cohort will guide the pivotal trial strategy. Active STARLIGHT-1 sites now include UC Davis Comprehensive Cancer Center, Baylor Scott & White Research Institute, and Oregon Health & Science University. Trial details are listed under NCT06343311 on ClinicalTrials.gov.
Estrella Immunopharma (NASDAQ: ESLA) announced activation of Baylor Scott & White Research Institute in Dallas, Texas as the second clinical site for its ongoing Phase I/II STARLIGHT-1 trial of EB103, a CD19-redirected ARTEMIS T‑cell therapy for relapsed or refractory B‑cell non-Hodgkin’s lymphoma.
According to Estrella, Baylor Scott & White Research Institute has begun screening and enrolling patients. The expansion phase of STARLIGHT-1 is a multi-center, open-label study evaluating the safety and efficacy of EB103 at the recommended Phase II dose in adults (≥18 years) with R/R B‑cell NHL. Data from this expansion cohort are expected to inform the pivotal trial strategy for EB103. As of the announcement date, active sites are UC Davis Comprehensive Cancer Center and Baylor Scott & White Research Institute. Trial details are listed on ClinicalTrials.gov under identifier NCT06343311.
Estrella Immunopharma (NASDAQ: ESLA) announced that the first patient has been successfully dosed in the dose-expansion phase of the ongoing STARLIGHT-1 Phase I/II trial of EB103, a CD19-redirected ARTEMIS T-cell therapy for relapsed/refractory B-cell non-Hodgkin’s lymphoma.
The expansion phase follows dose-escalation data in which, at a 6-month assessment of evaluable Phase I patients without CNS involvement, all patients who achieved a complete response remained in complete response. The multi-center, open-label expansion will evaluate safety and efficacy of EB103 at the recommended Phase II dose in adults with R/R B-cell NHL and will inform the pivotal trial strategy. Active sites include UC Davis Comprehensive Cancer Center and Baylor Scott & White Research Institute, with details listed under NCT06343311 on clinicaltrials.gov.
Estrella Immunopharma (NASDAQ: ESLA) said its CEO and CFO will attend one-on-one investor meetings at the D. Boral Capital 2026 Global Conference on May 7, 2026 at The Plaza Hotel, New York.
The participation offers direct meetings with institutional investors and strategic partners; investors should contact their D. Boral Capital representative to schedule.
Estrella Immunopharma (NASDAQ: ESLA) received initiating coverage from Zacks Small-Cap Research on March 23, 2026, with a $12.00 per share valuation. Zacks highlighted the differentiated ARTEMIS T-cell platform and encouraging Phase I STARLIGHT-1 data for EB103, including a 100% CR at Month 1 in the high-dose cohort (5 evaluable patients) and no Grade 3+ CRS reported.
The report notes favorable safety signals, heavily pretreated/high-risk patient enrollment, CR durations of 3–18 months to date, and that the valuation reflects Zacks SCR’s independent probability-adjusted DCF analysis.
Estrella Immunopharma (Nasdaq: ESLA) presented updated STARLIGHT-1 Phase I data showing promising clinical activity for EB103, a CD19-redirected ARTEMIS T-cell therapy, in aggressive B-cell non-Hodgkin lymphoma.
Key highlights: 100% complete response (CR) in the high-dose cohort at Month 1 (all CRs remain through data cutoff), response durations of 3–18 months with median DOCR not yet reached, one complete responder with PCNSL, and no treatment-related serious adverse events reported in the nine-patient cohort.